Last updated on July 2017

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome


Brief description of study

An Open-Label Study of Volanesorsen (IONIS 304801) Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Detailed Study Description

This is a multi-center, open-label study for Group 1: ISIS 304801-CS6 (index study) roll-over FCS patients, Group 2: ISIS 304801-CS16 (index study) roll-over FCS patients, and Group 3: FCS patients who did not participate in the ISIS 304801-CS6 or ISIS 304801-CS16 index studies. All patients will receive volanesorsen 300 mg once per week for 52 weeks. Patients will have the option of continuing dosing for an additional 52 weeks until an expanded access program is approved and available in their country.

Clinical Study Identifier: NCT02658175

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Patient Advocacy

IONIS Investigative Site
Huntington Beach, CA United States
  Connect »

Patient Advocacy

IONIS Investigative Site
San Francisco, CA United States
  Connect »

Patient Advocacy

IONIS Investigative Site
Boca Raton, FL United States
  Connect »

Patient Advocacy

IONIS Investigative Site
Boston, MA United States
  Connect »

Patient Advocacy

IONIS Investigative Site
Philadelphia, PA United States
  Connect »

Patient Advocacy

IONIS Investigative Site
Houston, TX United States
  Connect »

Patient Advocacy

IONIS Investigative Site
Norfolk, VA United States
  Connect »

Patient Advocacy

IONIS Investigative Site
Seattle, WA United States
  Connect »

Patient Advocacy

IONIS Investigative Site
Sao Paulo, Brazil
  Connect »

Patient Advocacy

IONIS Investigative Site
Vancouver, BC Canada
  Connect »

Patient Advocacy

IONIS Investigative Site
Chicoutimi, QC Canada
  Connect »

Patient Advocacy

IONIS Investigative Site
Montreal, QC Canada
  Connect »

Patient Advocacy

IONIS Investigative Site
Quebec, QC Canada
  Connect »

Patient Advocacy

IONIS Investigative Site
Paris, France
  Connect »

Patient Advocacy

IONIS Investigative Site
Marseille Cedex 05, France
  Connect »

Patient Advocacy

IONIS Investigative Site
Nantes cedex 1, France
  Connect »

Patient Advocacy

IONIS Investigative Site
Berlin, Germany
  Connect »

Patient Advocacy

IONIS Investigative Site
Safed, Israel
  Connect »

Patient Advocacy

IONIS Investigative Site
Palermo, Italy
  Connect »

Patient Advocacy

IONIS Investigative Site
Roma, Italy
  Connect »

Patient Advocacy

IONIS Investigative Site
Rome, Italy
  Connect »

Patient Advocacy

IONIS Investigative Site
Amsterdam-Zuidoost, Netherlands
  Connect »

Patient Advocacy

IONIS Investigative Site
Cape Town, South Africa
  Connect »

Patient Advocacy

IONIS Investigative Site
Barcelona, Spain
  Connect »

Patient Advocacy

IONIS Investigative Site
La Coruna-Galicia, Spain
  Connect »

Patient Advocacy

IONIS Investigative Site
Madrid, Spain
  Connect »

Patient Advocacy

IONIS Investigative Site
Sevilla, Spain
  Connect »

Patient Advocacy

IONIS Investigative Site
Zaragoza, Spain
  Connect »

Patient Advocacy

IONIS Investigative Site
Birmingham, United Kingdom
  Connect »

Patient Advocacy

IONIS Investigative Site
London, United Kingdom
  Connect »

Patient Advocacy

IONIS Investigative Site
Manchester, United Kingdom
  Connect »